Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: Coal Miner who wrote (634)	7/18/1998 11:52:00 AM
From: Graham Marshman	Respond to of 4028

Science info. Some of you may remember a brief exchange with Dr. Epstein with regard to CSI news release. He had some comments on the news. Some explanatory comments from CSI (re-posted from MCRR thread to Dr Epstein) are below. Graham PS I'm out of town for three days and come back to the stock at 2 1/4 - not bad! --repost from MCRR--------> Hi again. After our last exchange on the CYGS science, I did get some comments from CYGS resident biologist, see below. Hope these do clarify the situation some. Your comments truly appreciated. Graham ---------------> Dr. Epstein: On July 6, 1998, Cryogenic Solutions, Inc., announced that they had designed, constructed, and tested a vector that could synthesize single-stranded DNA in vivo. This announcement elicited an e-mail message which was posted the same day. You presented a brief overview of gene expression and gave your rendition of Crick's central dogma. You also raised four points in your message that are addressed here. Point#1: We are well aware that the synthesis of DNA from RNA is not a new finding in molecular biology. However, we can claim, as a first, that we have constructed a DNA vector that can synthesize any desired single-stranded DNA from an RNA template in vivo, therefore, it is a scientific breakthrough Point#2: The anticipated primary use for this vector is for use in antisense therapies, not as a vector for use in gene therapies. Point#3: The problem we are working on does indeed involve novel and specific molecular biological techniques. Point#4: The central dogma, as first presented by Francis Crick (1958, Symp. Soc. Exp. Biol., The Biological Replication of Macromolecules, XII, 138), does not state the flow of information is simply DNA to RNA to protein. Crick anticipated that the flow of information could indeed, in some circumstances, go from RNA to DNA, e.g., in retroviruses, as the discovery of reverse transcriptase by Temin in 1970 showed. The central dogma does flatly state that the flow of information can not be from protein to either protein or to nucleic acid. The simplest way to present the central dogma is nucleic acid to nucleic acid to protein. For a discussion by Crick on how the central dogma is misunderstood and misstated, see Crick, 1970, Nature, 227:561.